Belite Bio Receives IND Approval From FDA to Begin Clinical Trials With LBS-008 for Macular Degeneration and Stargardt Disease

FDA Approval

 Belite Bio, a subsidiary of Lin Bioscience focused on targeting untreatable age-related metabolic diseases, announced that the U.S. FDA approved its Investigational New Drug application (IND) for LBS-008 (BPN-14967) for the treatment of atrophic Age-related Macular Degeneration (commonly known as dry AMD) and Stargardt disease.  LBS-008 will be one of the first drugs to graduate from the US National Institute of Health's (NIH) Blueprint Neurotherapeutics Network (Blueprint Program), which has funded LBS-008's discovery and development, and will continue to provide support and funding until the completion of its Phase 1 single ascending dose (SAD) clinical trial.

A phase 1 study commenced in Australia in October 2018 and is expected to complete this study during the 2nd half of 2019.

About Atrophic Age-related Macular Degeneration and Stargardt Disease

Dry Age-Related Macular Degeneration (AMD) and Stargardt Disease are untreatable conditions that cause vision loss in adults and children, respectively.

Age-related Macular Degeneration (AMD) is a disease that can cause irreversible loss of central vision, which is used for seeing fine details during activities such as re...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee